AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease

Results suggest 67% objective response rate in second-line+ chronic graft versus host disease; Phase III study is already testing Imbruvica for new onset disease.

SAN DIEGO – Johnson & Johnson/AbbVie Inc.'s ambitious expansion plans for the blockbuster BTK inhibitor Imbruvica got a leg up with promising updated data from a Phase I/II trial of graft-versus-host disease presented in a late-breaker session at the American Society of Hematology meeting Dec. 5.

After allogenic stem cell and bone marrow transplants, donor cells may attack the body, causing GVHD, which can develop into...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category